IDSA/SHEA 2021 Recommendations for Tapered‑and‑Pulsed Oral Vancomycin in Recurrent C. difficile Infection

Indications and Patient Selection

• The 2021 IDSA/SHEA guidelines recommend a tapered‑and‑pulsed oral vancomycin regimen as an alternative treatment for patients experiencing a second or subsequent recurrence of C. difficile infection, especially when they are high‑risk (e.g., age > 65 years or prior treatment failures). 1
• Elderly adults (> 65 years) have an increased risk of recurrence, supporting the use of an extended regimen in this population. [2][4]

Dosing Regimen (Guideline‑Based Example)

This schedule reflects the IDSA/SHEA‑endorsed tapered/pulsed regimen for recurrent CDI. [1][2]3

Rationale and Expected Benefits

• High‑dose phase suppresses vegetative C. difficile while allowing gradual restoration of the intestinal microbiome. [1][3]
• Intermittent pulse dosing prevents spore germination by maintaining periodic antimicrobial pressure. 2
• Compared with a standard 10‑day vancomycin course, the tapered‑and‑pulsed approach reduces recurrence risk (standard courses show ≥ 20 % recurrence). 1

Alternative Regimens

• An alternative guideline‑endorsed option is vancomycin 125 mg four times daily for 10 days followed by rifaximin 400 mg three times daily for 20 days; however, the tapered‑and‑pulsed regimen is generally preferred when cost or drug availability is a concern. [1][3]

Adjunctive Therapies

• Adding a single dose of bezlotoxumab (10 mg/kg IV) during vancomycin therapy is advised for patients with multiple recurrence risk factors (age > 65 years, prior episodes). Caution is required in patients with a history of congestive heart failure. [1][2]4

Monitoring and Safety Considerations

• Renal function should be monitored throughout the extended vancomycin course, especially in older adults, because oral vancomycin can achieve measurable serum levels in the presence of inflamed intestinal mucosa. (Monitoring recommendation derived from guideline context.)

Implementation Tips and Common Pitfalls

• Do not use IV vancomycin for CDI—it is ineffective for colonic infection. 1
• Continue oral vancomycin for at least 5 days after any concurrent systemic antibiotics are finished to avoid premature discontinuation. 1
• The tapered‑and‑pulsed regimen specifically employs 125 mg doses; higher doses (e.g., 500 mg) are not required for this schedule. 1
• Clearly counsel patients that the pulse phase involves dosing every 2–3 days, not daily, to prevent confusion. 1

Future Steps (Fecal Microbiota Transplantation)

• The IDSA/SHEA guidelines state that appropriate antibiotic therapy should be attempted for at least two recurrences (i.e., three CDI episodes) before offering fecal microbiota transplantation (FMT). After completing the third treatment course, FMT should be strongly considered if another recurrence occurs. [1][3]